{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:05:11Z","timestamp":1784905511079,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Autophagy induction has recently emerged as a mechanism of resistance to FLT3 inhibitors (FLT3i) in patients with\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD mutant acute myeloid leukemia (AML). Here, we assessed the molecular mechanisms of autophagy inhibition associated with FLT3i and its impact on cell survival and pharmacological resistance. In\n                    <jats:italic>FLT3<\/jats:italic>\n                    -ITD AML cell lines (MOLM13 and MV4-11), treatment with first- and second-generation FLT3i (midostaurin and quizartinib, respectively) induced autophagy. Combining FLT3i with autophagy inhibitors further decreased cell viability and increased cell apoptosis in both cell lines and in primary patient samples. Label-free quantification proteomics of MOLM13 cells revealed that RFC4 (Replication Factor C Subunit 4), an autophagy regulator linked to increased chemosensitivity, and GATD3\/C21orf33 (Glutamine Amidotransferase Class 1 Domain Containing 3) proteins were upregulated only in the combined group, while 11 proteins mostly associated with chemoresistance were downregulated. In vivo, the combination of midostaurin and autophagy inhibition improved overall survival in MOLM13-transplanted mice.\n                    <jats:italic>ATG5<\/jats:italic>\n                    - (Autophagy Related 5) and\n                    <jats:italic>ATG7<\/jats:italic>\n                    -knockdown (Autophagy Related 7) increased sensitivity to first- and second-generation FLT3i in MOLM13 cells. To investigate the potential of autophagy inhibition in overcoming FLT3i resistance, we generated MV4-11 cells resistant to quizartinib (MV4-11QR). The resistant cell line exhibited higher basal levels of autophagy compared to the parental cell line. The combination of quizartinib and chloroquine demonstrated a synergistic effect in MV4-11QR cells and this effect was associated with greater inhibition of the FLT3 receptor compared to the monotherapies. Therefore, combining FLT3i with autophagy inhibition enhances the FLT3i antileukemic efficacy and overcomes pharmacological resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41420-026-03037-7","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:35:39Z","timestamp":1774384539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemia"],"prefix":"10.1038","volume":"12","author":[{"given":"Manuela","family":"Albuquerque de Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunno Gilberto","family":"Santos de Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Pereira-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio Bruno","family":"Alves-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Peixoto","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia Bassani Lins","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleide Lucia Ara\u00fajo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila Santos","family":"Scheucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-8555","authenticated-orcid":false,"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-289X","authenticated-orcid":false,"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"3037_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3037_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.cell.2017.11.007","volume":"171","author":"JEJ Rasko","year":"2017","unstructured":"Rasko JEJ, Hughes TP. First Approved Kinase Inhibitor for AML. Cell. 2017;171:981.","journal-title":"Cell"},{"key":"3037_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111:312\u201322.","journal-title":"Cancer Sci"},{"key":"3037_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10:612880.","journal-title":"Front Oncol"},{"key":"3037_CR5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1182\/blood-2018-99-115702","volume":"132","author":"S Qiu","year":"2018","unstructured":"Qiu S, Paterson AJ, Abraham A, He J, Shah M, Agarwal P, et al. Role of enhanced autophagy in resistance of FLT3-ITD AML stem cells to FLT3 TKI treatment. Blood. 2018;132:1358\u20131358.","journal-title":"Blood"},{"key":"3037_CR6","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1038\/s41375-022-01678-y","volume":"36","author":"SE Koschade","year":"2022","unstructured":"Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Th\u00f6lken M, et al. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022;36:2396\u2013407.","journal-title":"Leukemia"},{"key":"3037_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/onc.2017.376","volume":"37","author":"Q Heydt","year":"2018","unstructured":"Heydt Q, Larrue C, Saland E, Bertoli S, Sarry JE, Besson A, et al. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. Oncogene. 2018;37:787\u201397.","journal-title":"Oncogene"},{"key":"3037_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74168-z","volume":"14","author":"BG Santos De Macedo","year":"2024","unstructured":"Santos De Macedo BG, Albuquerque De Melo M, Pereira-Martins DA, Machado-Neto JA, Traina F. Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia. Sci Rep. 2024;14:23882.","journal-title":"Sci Rep"},{"key":"3037_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189214","volume":"1879","author":"BG Santos De Macedo","year":"2024","unstructured":"Santos De Macedo BG, Albuquerque De Melo M, Pereira-Martins DA, Machado-Neto JA, Traina F. An updated outlook on autophagy mechanism and how it supports acute myeloid leukemia maintenance. Biochim Biophys Acta BBA Rev Cancer. 2024;1879:189214.","journal-title":"Biochim Biophys Acta BBA Rev Cancer"},{"key":"3037_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/ncb2788","volume":"15","author":"P Boya","year":"2013","unstructured":"Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol. 2013;15:713\u201320.","journal-title":"Nat Cell Biol"},{"key":"3037_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","volume":"40","author":"AK Jayavelu","year":"2022","unstructured":"Jayavelu AK, Wolf S, Buettner F, Alexe G, H\u00e4upl B, Comoglio F, et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. 2022;40:301\u2013.e12.","journal-title":"Cancer Cell"},{"key":"3037_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s12094-022-02804-z","volume":"24","author":"A Khan","year":"2022","unstructured":"Khan A, Singh VK, Thakral D, Gupta R. Autophagy in acute myeloid leukemia: a paradoxical role in chemoresistance. Clin Transl Oncol. 2022;24:1459\u201369.","journal-title":"Clin Transl Oncol"},{"key":"3037_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-022-01262-y","volume":"15","author":"W Seo","year":"2022","unstructured":"Seo W, Silwal P, Song IC, Jo EK. The dual role of autophagy in acute myeloid leukemia. J Hematol OncolJ Hematol Oncol. 2022;15:51.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"3037_CR14","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1038\/s41401-023-01112-8","volume":"44","author":"HL Wang","year":"2023","unstructured":"Wang HL, Li JN, Kan WJ, Xu GY, Luo GH, Song N, et al. Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway. Acta Pharm Sin. 2023;44:2296\u2013306.","journal-title":"Acta Pharm Sin"},{"key":"3037_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2174\/1574892815666210106111012","volume":"16","author":"W Fong","year":"2021","unstructured":"Fong W, To KKW. Repurposing chloroquine analogs as an adjuvant cancer therapy. Recent Pat Anticancer Drug Discov. 2021;16:204\u201321.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"3037_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-022-01267-6","volume":"20","author":"AJ Smith","year":"2022","unstructured":"Smith AJ, Advani J, Brock DC, Nellissery J, Gumerson J, Dong L, et al. GATD3A, a mitochondrial deglycase with evolutionary origins from gammaproteobacteria, restricts the formation of advanced glycation end products. BMC Biol. 2022;20:68.","journal-title":"BMC Biol"},{"key":"3037_CR17","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41417-022-00501-1","volume":"29","author":"T Hu","year":"2022","unstructured":"Hu T, Pan C, Zhang T, Ni M, Wang W, Zhang S, et al. Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4. Cancer Gene Ther. 2022;29:1773\u201390.","journal-title":"Cancer Gene Ther"},{"key":"3037_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25664-7","volume":"12","author":"A Khateb","year":"2021","unstructured":"Khateb A, Deshpande A, Feng Y, Finlay D, Lee JS, Lazar I, et al. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors. Nat Commun. 2021;12:5397.","journal-title":"Nat Commun"},{"key":"3037_CR19","doi-asserted-by":"publisher","first-page":"9189","DOI":"10.18632\/oncotarget.3279","volume":"6","author":"A Nogami","year":"2015","unstructured":"Nogami A, Oshikawa G, Okada K, Fukutake S, Umezawa Y, Nagao T, et al. FLT3-ITD confers resistance to the PI3K\/Akt pathway inhibitors by protecting the mTOR\/4EBP1\/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget. 2015;6:9189\u2013205.","journal-title":"Oncotarget"},{"key":"3037_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3498","volume":"25","author":"W Liu","year":"2023","unstructured":"Liu W, Xie A, Xiong J, Li S, Yang L, Liu W. WDR3 promotes stem cell-like properties in prostate cancer by inhibiting USF2-mediated transcription of RASSF1A. J Gene Med. 2023;25:e3498.","journal-title":"J Gene Med"},{"key":"3037_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13046-021-01879-w","volume":"40","author":"W Su","year":"2021","unstructured":"Su W, Zhu S, Chen K, Yang H, Tian M, Fu Q, et al. Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. J Exp Clin Cancer Res. 2021;40:88.","journal-title":"J Exp Clin Cancer Res"},{"key":"3037_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12876-023-02984-0","volume":"23","author":"F Lou","year":"2023","unstructured":"Lou F, Zhang M. RFC2 promotes aerobic glycolysis and progression of colorectal cancer. BMC Gastroenterol. 2023;23:353.","journal-title":"BMC Gastroenterol"},{"key":"3037_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182677","volume":"14","author":"J Huang","year":"2023","unstructured":"Huang J, Zhou H, Tan C, Mo S, Liu T, Kuang Y. The overexpression of actin related protein 2\/3 complex subunit 1B(ARPC1B) promotes the ovarian cancer progression via activation of the Wnt\/\u03b2-catenin signaling pathway. Front Immunol. 2023;14:1182677.","journal-title":"Front Immunol"},{"key":"3037_CR24","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/ijms23031476","volume":"23","author":"Y Gamallat","year":"2022","unstructured":"Gamallat Y, Zaaluk H, Kish EK, Abdelsalam R, Liosis K, Ghosh S, et al. ARPC1B is associated with lethal prostate cancer and its inhibition decreases cell invasion and migration in vitro. Int J Mol Sci. 2022;23:1476.","journal-title":"Int J Mol Sci"},{"key":"3037_CR25","doi-asserted-by":"crossref","unstructured":"Cheng S, Mao Q, Dong Y, Ren J, Su L, Liu J, et al. GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer. PLOS ONE. 2017;12:e0182696.","DOI":"10.1371\/journal.pone.0182696"},{"key":"3037_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/gutjnl-2017-314983","volume":"68","author":"L Wan","year":"2019","unstructured":"Wan L, Yu W, Shen E, Sun W, Liu Y, Kong J, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019;68:118\u201329.","journal-title":"Gut"},{"key":"3037_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.780023","volume":"9","author":"W She","year":"2021","unstructured":"She W, Shao J, Jia R. Targeting splicing factor SRSF6 for cancer therapy. Front Cell Dev Biol. 2021;9:780023.","journal-title":"Front Cell Dev Biol"},{"key":"3037_CR28","doi-asserted-by":"crossref","unstructured":"Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, et al. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. Proc Natl Acad Sci USA. 2018;115. Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1714573115.","DOI":"10.1073\/pnas.1714573115"},{"key":"3037_CR29","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1242\/jcs.195057","volume":"129","author":"MP Thom\u00e9","year":"2016","unstructured":"Thom\u00e9 MP, Filippi-Chiela EC, Villodre ES, Migliavaca CB, Onzi GR, Felipe KB, et al. Ratiometric analysis of Acridine Orange staining in the study of acidic organelles and autophagy. J Cell Sci. 2016;129:4622\u201332.","journal-title":"J Cell Sci"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03037-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:24:35Z","timestamp":1774985075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03037-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3037"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03037-7","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}